A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 13, Issue 2, 2015, Pages 113-123

  Courtney, Kevin D ^a   Manola, Judith B ^a   Elfiky, Aymen A ^a   Ross, Robert ^a   Oh, William K ^a   Yap, Jeffrey T ^b   Van Den Abbeele, Annick D ^b   Ryan, Christopher W ^c   Beer, Tomasz M ^c   Loda, Massimo ^a,b   Priolo, Carmen ^a   Kantoff, Philip ^a   Taplin, Mary Ellen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

mTOR; PI3K; Positron emission tomography; Prostatic adenocarcinoma; PTEN

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DEXAMETHASONE; DOCETAXEL; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC RHINITIS; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECUBITUS; DESQUAMATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTRITIS; GENITAL EDEMA; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RASH; RIGOR; SIDE EFFECT; SWEATING; TASTE DISORDER; THROMBOCYTOPENIA; TOOTH INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ULCER; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; CLINICAL TRIAL; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84924580967     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.08.007     Document Type: Article

References (42)

1. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501
2. M.E. McMenamin, P. Soung, and S. Perera Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Res 59 1999 4291 4296
3. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
4. K. Sircar, M. Yoshimoto, and F.A. Monzon PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer J Pathol 218 2009 505 513
5. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 1998 13375 13378
6. X. Wu, K. Senechal, and M.S. Neshat The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway Proc Natl Acad Sci U S A 95 1998 15587 15591
7. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
8. N. Gao, Z. Zhang, and B.H. Jiang Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer Biochem Biophys Res Commun 310 2003 1124 1132
9. V. Grunwald, L. DeGraffenried, and D. Russel Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells Cancer Res 62 2002 6141 6145
10. H.G. van der Poel Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells J Urol 172 2004 1333 1337
11. H.G. van der Poel, C. Hanrahan, and H. Zhong Rapamycin induces Smad activity in prostate cancer cell lines Urol Res 30 2003 380 386
12. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 2001 807 826
13. D.D. Sarbassov, S.M. Ali, and D.H. Kim Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302
14. D.A. Krueger, M.M. Care, and K. Holland Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
15. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
16. J.C. Yao, M.H. Shah, and T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
17. P.K. Majumder, P.G. Febbo, and R. Bikoff mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat Med 10 2004 594 601
18. George DJ, Armstrong AJ, Creel P, et al. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC). ASCO 2008 Genitourinary Cancers Symposium 2008; abstract 181.
19. R.J. Amato, J. Jac, and T. Mohammad Pilot study of rapamycin in patients with hormone-refractory prostate cancer Clin Genitourin Cancer 6 2008 97 102
20. A.J. Armstrong, T. Shen, and S. Halabi A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer Clin Genitourin Cancer 11 2013 397 406
21. A.J. Templeton, V. Dutoit, and R. Cathomas Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) Eur Urol 64 2013 150 158
22. T.M. Morgan, T.E. Pitts, and T.S. Gross RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid Prostate 68 2008 861 871
23. T. Kosaka, A. Miyajima, and S. Shirotake Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer J Urol 185 2011 2376 2381
24. Y. Yasumizu, A. Miyajima, and T. Kosaka Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer J Urol 191 2014 227 234
25. A.L. Edinger, C.M. Linardic, and G.G. Chiang Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells Cancer Res 63 2003 8451 8460
26. G.V. Thomas, C. Tran, and I.K. Mellinghoff Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 2006 122 127
27. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
28. H. Young, R. Baum, and U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782
29. A. O'Donnell, S. Faivre, and H.A. Burris 3rd Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
30. C. Tanaka, T. O'Reilly, and J.M. Kovarik Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 26 2008 1596 1602
31. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
32. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
33. A.D. Van den Abbeele The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 suppl 2 2008 8 13
34. W.W. Ma, H. Jacene, and D. Song [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy J Clin Oncol 27 2009 2697 2704
35. K.E. O'Reilly, F. Rojo, and Q.B. She mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
36. S.Y. Sun, L.M. Rosenberg, and X. Wang Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 2005 7052 7058
37. D.D. Sarbassov, S.M. Ali, and S. Sengupta Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 2006 159 168
38. A. Carracedo, L. Ma, and J. Teruya-Feldstein Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065 3074
39. S. Jia, X. Gao, and S.H. Lee Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention Cancer Discov 3 2013 44 51
40. B.S. Carver, C. Chapinski, and J. Wongvipat Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
41. D.J. Mulholland, L.M. Tran, and Y. Li Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth Cancer Cell 19 2011 792 804
42. M. Nakabayashi, L. Werner, and K.D. Courtney Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer BJU Int 110 2012 1729 1735